CD19 and B-cell non-Hodgkin lymphoma: Thus, the results of the NCT04088890 and ChiCTR1800019298 studies indicate the possibility of effective therapy for patients with r/r aggressive B-cell lymphomas after CD19-specific CAR-T therapy.